Neuren Pharmaceuticals Limited
ASX: NEU
Further short-term price corrections possible despite strong fundamental value.
(Source: TradingView) 3-Month Performance Profile of NEU compared to the ASX 200 (XJO).
Neuren has experienced a significant financial decline in the first half of 2024, with revenues falling to $24 million and earnings decreasing to $8 million, in contrast to $62 million in rev
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
